Transforming Large B-Cell Lymphoma (LBCL): CAR T and Novel Agents : Episode 12

Opinion

Video

December 19, 2023

Lisocabtagene Maraleucel: A Review of TRANSCEND NHL 001 in R/R LBCL

Author(s):

Gain insights into treatment outcomes of CAR T, highlighting lisocabtagene maraleucel and the TRANSCEND NHL 001 study for R/R LBCL.

EP: 1.Understanding LBCL: Presentation, Diagnosis, and Prognostic Indicators

EP: 2.Large B-Cell Lymphoma: Treatment Approaches and Evolving Therapies

EP: 3.Advancing Lymphoma Treatments: CAR T-Cell and Bispecific Therapies

EP: 4.CAR T-Cell Therapy’s Impact on Lymphoma Management

EP: 5.Real-World Use of CAR T-Cell Therapy in Patients with Lymphoma

EP: 6.Challenges in CAR T-Cell Therapy for Lymphoma

EP: 7.Exploring LBCL: Transplant Eligibility and Second Line Treatment Selection of Novel Agents

EP: 8.CAR T: A Review of Clinical Data for Second Line Treatments of Large B-Cell Lymphoma

EP: 9.Approaches to Treatment Sequencing in LBCL

EP: 10.Innovations in Immunotherapy: CAR T-Cells, Allogeneic Approaches, and Bispecifics

EP: 11.ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL

Now Viewing

EP: 12.Lisocabtagene Maraleucel: A Review of TRANSCEND NHL 001 in R/R LBCL

EP: 13.Observations in Progression Post-CAR T for Lymphoma

EP: 14.Emerging Bispecifics in the Treatment Paradigm for R/R LBCL

EP: 15.Future Perspectives in Large B-Cell Lymphoma

Related Content

December 3rd 2024

OncLive’s November Roundup of Key FDA Approvals in Oncology

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

December 2nd 2024

Vice Chair of the B-Cell Lymphomas NCCN Guidelines Maps Critical Changes From 2024

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

November 30th 2024

The OncFive: Top Oncology Articles for the Week of 11/24

November 29th 2024

Obe-Cel Approval Expands CAR T-Cell Therapy Options in Relapsed/Refractory ALL